Project Grant R43AI189037
Award Date 9/22/25
Completion Date 2/28/26
Dollars Obligated $313K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Torrance, CA 90502, USA
Similar Awards
- This $2,483,910 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) supports research to investigate novel genetic mechanisms underlying inborn errors of immunity and immune dysregulation disorders. The key objectives are: Mapping genes prone to autosomal random monoallelic expression (ARMAE) in the immune system, defining the underlying epigenetic marks, and validating the findings in families with...
- This $420,771 federal Project Grant from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to develop a targeted genetic therapy for Artemis-deficient SCID, a form of primary immunodeficiency. The award, provided to the Regents of the University of Minnesota, aims to evaluate the feasibility of using an adenosine base editing approach to functionally restore a prevalent nonsense mutation in the Artemis gene and...
- This federal Project Grant award, valued at $3,147,392.00, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research at the Childrens Hospital Medical Center in Cincinnati, Ohio to investigate how dendritic cells and the unfolded protein response (UPR) play a role in generating pathogen-specific Th17 immune responses. The research aims to advance the understanding of...
- This $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports the development of a GMP-compliant E. coli dihydrofolate reductase (EDHFR) vector. This vector will be used to monitor the biodistribution and trafficking of investigational chimeric antigen receptor (CAR) T cell therapies through positron emission tomography (PET) imaging. The goals are to provide a...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $300,000 Project Grant to Electronic Biosciences, Inc. to develop a novel point-of-care technology for monitoring immunosuppressant drug levels. The key product being developed is a portable, fingerstick-based testing system that can provide convenient and frequent immunosuppressant drug level measurements. This will enable more precise dosing for...
- The Project Grant award of $122,839 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Children's Hospital Corporation (Boston Children's Hospital) aims to delineate the influence of macrophage ontogeny on their specification and identify strategies to target dysregulated macrophage subsets in diseases such as atopic dermatitis, Langerhans cell histiocytosis, and graft-vs-host disease. The research approach encompasses...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $489,500 project grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Children's Hospital Corporation (Boston Children's Hospital) to conduct research aimed at overcoming technical obstacles in the elucidation of B cell antigen receptor assembly and lateral interaction. The research project, with a period of performance from July 2025 to June 2027, seeks to develop a better...
- This federal Project Grant award for $306,825.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The funding supports the development of RG0401, an ex vivo autologous CD34+ hematopoietic progenitor and stem cell-based gene therapy by Rheumagen, Inc. to treat refractory rheumatoid arthritis (RA). The therapy aims to replace the DRB1*04:01 RA-inducing allele with a resistant allele to...
- This federal Project Grant award of $170,000 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855). The funding supports research by Prokaryotics Incorporated, a pharmaceutical and biotechnology company, to develop novel antifungal inhibitors targeting the glycosylphosphatidylinositol (GPI) ethanolamine phosphate transferase enzyme MCD4. This research aims to address the critical...
- This $489,500 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to establish a new in vitro lung alveolar epithelial cell organoid model from human bronchoalveolar lavage fluid (BALF) for studying Mycobacterium tuberculosis (MTB) infection and the effects of the experimental host-directed therapeutic nitazoxanide. The research aims to advance the understanding of human innate immune...